MedTrace Logo

To Evaluate the Pharmacokinetic Characteristics and Safety in Healthy Volunteers

NCT06361277 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2024-04-11

No results posted yet for this study

Summary

The objective is to evaluate the safety and pharmacokinetic characteristics after co-administration of JW0202 and C2202 and co-administration of C2205 and JW0201 in healthy volunteers under fasting conditions

Conditions

  • Healthy

Interventions

DRUG

Reference Drug or Test Drug

Tablet, Oral, QD for 1 Day, Washout period is more than 7 days after administration

Sponsors & Collaborators

Principal Investigators

  • MinGul Kim · Jeonbuk National University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
19 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-11-03
Primary Completion
2023-11-20
Completion
2023-11-27

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06361277 on ClinicalTrials.gov